The purpose of this study is to determine whether incretin-based drugs (used to treat type 2
diabetes) taken either alone in or combination with other anti-diabetic drugs are associated
with an increased risk of pancreatic cancer (PC) compared to sulfonylureas.
The investigators will carry out separate population based cohort studies using
administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts
will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs
entered the market, with follow-up until hospitalization for PC. The results from the
separate sites will be combined to provide an overall assessment of the risk of PC in users
of incretin-based drugs and by class of incretin-based drugs.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network, Canada